stockrowMARKER THERAPEUTICS, INC.
MRKR Healthcare Biotechnology
MARKER THERAPEUTICS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 46.2% from fiscal 2024.
- Revenue
- −51.0%
- EPS
- +69.0%
- Free cash flow
- −97.8%
Quarter to June 2026, against a year earlier
Follow MRKR
Alert me
MARKER THERAPEUTICS, INC. (MRKR) EV/Sales
As of 6 November 2026, MARKER THERAPEUTICS, INC. (MRKR) trades at a EV/Sales of 1.9×. Over the past ten years it has ranged from −6.8× (February 2022) to 171× (July 2021); the current reading is higher than 63% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.1× | 33.07% |
| FY2024 | 1.6× | (84.41%) |
| FY2023 | 10.2× | 199.40% |
| FY2022 | 3.4× | (75.77%) |
| FY2021 | 14.0× | (68.30%) |
| FY2020 | 44.2× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2025 | 2.1× | — |
| Sep 2025 | −0.5× | — |
| Jun 2025 | 2.1× | 608.93% |
| Mar 2025 | 0.3× | (81.42%) |
| 17 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VAXX Vaxxinity, Inc. compare | −94.2× |
| ABOS Acumen Pharmaceuticals, Inc. compare | −25.4× |
| ATYR aTyr Pharma, Inc. compare | −3.5× |
| NEUP Neuphoria Therapeutics Inc. compare | −0.4× |
| CTXR Citius Pharmaceuticals, Inc. compare | n/m |
| ADAPY Adaptimmune Therapeutics PLC compare | 0.1× |
| MRKR MARKER THERAPEUTICS, INC. | 1.9× |
| KYNB Kyntra Bio Inc compare | 15.5× |
| PLUR Pluri Inc. compare | 32.0× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)